Multiple groups subsequently launched clinical trials to deliver subretinal RPE65 via an AAV vector to patients with Leber congenital amaurosis [5,6,7], reinvigorating research in gene therapy. This evidence concerns the gene RPE65 and Leber congenital amaurosis.